These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 32989463)
41. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. Payne RO; Milne KH; Elias SC; Edwards NJ; Douglas AD; Brown RE; Silk SE; Biswas S; Miura K; Roberts R; Rampling TW; Venkatraman N; Hodgson SH; Labbé GM; Halstead FD; Poulton ID; Nugent FL; de Graaf H; Sukhtankar P; Williams NC; Ockenhouse CF; Kathcart AK; Qabar AN; Waters NC; Soisson LA; Birkett AJ; Cooke GS; Faust SN; Woods C; Ivinson K; McCarthy JS; Diggs CL; Vekemans J; Long CA; Hill AV; Lawrie AM; Dutta S; Draper SJ J Infect Dis; 2016 Jun; 213(11):1743-51. PubMed ID: 26908756 [TBL] [Abstract][Full Text] [Related]
42. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites. Zhang D; Pan W Infect Immun; 2005 Oct; 73(10):6530-6. PubMed ID: 16177327 [TBL] [Abstract][Full Text] [Related]
43. APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces Bjerkan L; Visweswaran GRR; Gudjonsson A; Labbé GM; Quinkert D; Pattinson DJ; Spång HCL; Draper SJ; Bogen B; Braathen R Front Immunol; 2021; 12():720550. PubMed ID: 34733274 [TBL] [Abstract][Full Text] [Related]
44. The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines. Spiegel H; Boes A; Kastilan R; Kapelski S; Edgue G; Beiss V; Chubodova I; Scheuermayer M; Pradel G; Schillberg S; Reimann A; Fischer R Biotechnol J; 2015 Oct; 10(10):1651-9. PubMed ID: 25913888 [TBL] [Abstract][Full Text] [Related]
45. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes. de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL Malar J; 2011 Sep; 10():266. PubMed ID: 21920045 [TBL] [Abstract][Full Text] [Related]
46. Structural basis for inhibition of erythrocyte invasion by antibodies to Chen L; Xu Y; Wong W; Thompson JK; Healer J; Goddard-Borger ED; Lawrence MC; Cowman AF Elife; 2017 Feb; 6():. PubMed ID: 28195530 [No Abstract] [Full Text] [Related]
47. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Arumugam TU; Takeo S; Yamasaki T; Thonkukiatkul A; Miura K; Otsuki H; Zhou H; Long CA; Sattabongkot J; Thompson J; Wilson DW; Beeson JG; Healer J; Crabb BS; Cowman AF; Torii M; Tsuboi T Infect Immun; 2011 Nov; 79(11):4523-32. PubMed ID: 21896773 [TBL] [Abstract][Full Text] [Related]
48. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229 [TBL] [Abstract][Full Text] [Related]
49. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35. Kalra A; Edula JR; Gupta PK; Pandey AK; Chauhan VS PLoS One; 2016; 11(10):e0165720. PubMed ID: 27798691 [TBL] [Abstract][Full Text] [Related]
50. Genetic diversity and antibody responses against Plasmodium falciparum vaccine candidate genes from Chhattisgarh, Central India: Implication for vaccine development. Patel P; Bharti PK; Bansal D; Raman RK; Mohapatra PK; Sehgal R; Mahanta J; Sultan AA; Singh N PLoS One; 2017; 12(8):e0182674. PubMed ID: 28787005 [TBL] [Abstract][Full Text] [Related]
51. Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children. Irani V; Ramsland PA; Guy AJ; Siba PM; Mueller I; Richards JS; Beeson JG Clin Infect Dis; 2015 Oct; 61(8):1244-52. PubMed ID: 26136391 [TBL] [Abstract][Full Text] [Related]
52. PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen. Zhao X; Chang Z; Tu Z; Yu S; Wei X; Zhou J; Lu H; Jiang N; Chen Q Malar J; 2014 Dec; 13():490. PubMed ID: 25495792 [TBL] [Abstract][Full Text] [Related]
53. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. Payne RO; Silk SE; Elias SC; Miura K; Diouf A; Galaway F; de Graaf H; Brendish NJ; Poulton ID; Griffiths OJ; Edwards NJ; Jin J; Labbé GM; Alanine DG; Siani L; Di Marco S; Roberts R; Green N; Berrie E; Ishizuka AS; Nielsen CM; Bardelli M; Partey FD; Ofori MF; Barfod L; Wambua J; Murungi LM; Osier FH; Biswas S; McCarthy JS; Minassian AM; Ashfield R; Viebig NK; Nugent FL; Douglas AD; Vekemans J; Wright GJ; Faust SN; Hill AV; Long CA; Lawrie AM; Draper SJ JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093263 [TBL] [Abstract][Full Text] [Related]
55. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540 [TBL] [Abstract][Full Text] [Related]
56. Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine. Jiang L; Gaur D; Mu J; Zhou H; Long CA; Miller LH Proc Natl Acad Sci U S A; 2011 May; 108(18):7553-8. PubMed ID: 21502513 [TBL] [Abstract][Full Text] [Related]
57. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain. Moll K; Pettersson F; Vogt AM; Jonsson C; Rasti N; Ahuja S; Spångberg M; Mercereau-Puijalon O; Arnot DE; Wahlgren M; Chen Q Infect Immun; 2007 Jan; 75(1):211-9. PubMed ID: 17074852 [TBL] [Abstract][Full Text] [Related]
58. Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies. King LDW; Pulido D; Barrett JR; Davies H; Quinkert D; Lias AM; Silk SE; Pattinson DJ; Diouf A; Williams BG; McHugh K; Rodrigues A; Rigby CA; Strazza V; Suurbaar J; Rees-Spear C; Dabbs RA; Ishizuka AS; Zhou Y; Gupta G; Jin J; Li Y; Carnrot C; Minassian AM; Campeotto I; Fleishman SJ; Noe AR; MacGill RS; King CR; Birkett AJ; Soisson LA; Long CA; Miura K; Ashfield R; Skinner K; Howarth MR; Biswas S; Draper SJ Cell Rep Med; 2024 Jul; 5(7):101654. PubMed ID: 39019011 [TBL] [Abstract][Full Text] [Related]
59. Differential antibody recognition of four allelic variants of the merozoite surface protein-2 (MSP-2) of Plasmodium falciparum. Tonhosolo R; Wunderlich G; Ferreira MU J Eukaryot Microbiol; 2001; 48(5):556-64. PubMed ID: 11596920 [TBL] [Abstract][Full Text] [Related]
60. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Boyle MJ; Reiling L; Feng G; Langer C; Osier FH; Aspeling-Jones H; Cheng YS; Stubbs J; Tetteh KK; Conway DJ; McCarthy JS; Muller I; Marsh K; Anders RF; Beeson JG Immunity; 2015 Mar; 42(3):580-90. PubMed ID: 25786180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]